法尔明集团公布 2026 年第三季度财务业绩；营收强劲增长，Joenja APDS 适应症拓展及 CVID 顶线数据将于 11 月公布

Pharming Group delivered robust financial results for the third quarter of 2026, posting total revenues of $117.6 million, which represents a 21% year-over-year growth and surpasses consensus analyst expectations. The growth was primarily driven by flagship product RUCONEST, which generated $93.8 million in revenue, reflecting stable demand and seasonal inventory adjustments. Management also provided updates on its broader clinical portfolio, including the Joenja APDS expansion and anticipated CVID topline data expected in November. These operational milestones validate the company's commercial strategy and strengthen its balance sheet for ongoing clinical trials. Investors responded favorably to the resilient top-line growth and clear regulatory roadmap for upcoming product indications. The positive performance reinforces confidence in Pharming Group's ability to scale its rare disease treatment portfolio.